METASTATIC LUNG NON-SMALL CELL CARCINOMA
Clinical trials for METASTATIC LUNG NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC LUNG NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New radiation drug aims to slow bone tumors in advanced cancer
Disease control Not yet recruitingThis early-phase study tests a new drug (Sn-117m-DTPA) that delivers low-level radiation directly to bone tumors while being gentler on bone marrow. It is for people with prostate, breast, or lung cancer that has spread to the bones. The main goals are to find the safest dose and…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:26 UTC
-
New hope for advanced lung cancer patients: drug combo aims to reawaken immune system
Disease control Not yet recruitingThis study tests a new two-drug combination (SX-682 and atezolizumab) for people with advanced non-small cell lung cancer whose cancer continued to grow after chemotherapy and immunotherapy. The goal is to see if the combination can shrink tumors or slow the disease. About 32 adu…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 26, 2026 03:58 UTC
-
Light-Activated drug combo takes aim at Hard-to-Treat lung cancer
Disease control Not yet recruitingThis study tests a new combination treatment for people with advanced non-small cell lung cancer that has not responded to standard therapies. The treatment uses a light-activated drug (ASP-1929) plus an immunotherapy drug (cemiplimab) to target and kill cancer cells. About 27 ad…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 26, 2026 03:54 UTC
-
Could a smaller dose of this cancer drug work just as well? a new trial aims to find out.
Disease control Not yet recruitingThis study is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control advanced cancers that have spread or cannot be removed by surgery. The goal is to see if this cheaper, simpler approach works as well as the standard dose, which co…
Matched conditions: METASTATIC LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:04 UTC